Simplex Trading, LLC Sol Gel Technologies Ltd. Transaction History

Simplex Trading, LLC

$3.28 Billion
Q4 2024

A detailed history of Simplex Trading, LLC transactions in Sol Gel Technologies Ltd. stock. As of the latest transaction made, Simplex Trading, LLC holds 27 shares of SLGL stock, worth $16. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$16

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$0.43 - $1.65 $11 - $44	27 New	27 $0
Q2 2024 Jul 25, 2024	BUY	$0.66 - $1.05 $132 - $210	200 Added 38.02%	726 $0
Q1 2024 Apr 25, 2024	BUY	$0.95 - $1.5 $499 - $789	526 New	526 $0
Q1 2023 Apr 27, 2023	BUY	$3.44 - $5.32 $1,506 - $2,330	438 Added 202.78%	654 $2,000
Q4 2022 Feb 02, 2023	BUY	$4.26 - $5.22 $920 - $1,127	216 New	216 $0
Q2 2022 Aug 03, 2022	SELL	$4.1 - $7.36 $9,721 - $17,450	-2,371 Reduced 91.72%	214 $0
Q1 2022 May 02, 2022	BUY	$6.64 - $8.21 $10,424 - $12,889	1,570 Added 154.68%	2,585 $19,000
Q4 2021 Feb 23, 2022	BUY	$6.57 - $9.78 $6,668 - $9,926	1,015 New	1,015 $7,000

Others Institutions Holding SLGL

# of Institutions

Shares Held

5.31M

Call Options Held

12.8K

Put Options Held

Phoenix Holdings Ltd. Givatayim, L3

2.47M
Shares

$1.48 Million
0.03% of portfolio
Migdal Insurance & Financial Holdings Ltd.

1.23M
Shares

$736,528
0.02% of portfolio
Harel Insurance Investments & Financial Services Ltd.

920K
Shares

$552,199
0.01% of portfolio
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3

227K
Shares

$136,246
0.04% of portfolio
Raymond James Financial Inc St. Petersburg, FL

109K
Shares

$65,394
0.0% of portfolio

View Full List

About Sol-Gel Technologies Ltd.

Ticker SLGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,129,500
Market Cap $13.9M
Description
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...

More about SLGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account